LTQ Orbitrap XL FT-LC/MSn mass spectrometer

LTQ Orbitrap XL FT-LC/MSn 质谱仪

• 批准号: 7792882
• 负责人: Joseph DiDonato
• 金额: $ 50万
• 依托单位: CLEVELAND CLINIC LERNER COM-CWRU
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-03-25 至 2011-03-24
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7792882
• 关键词: Affect; Amino Acid Sequence; Area; Biological Markers; Clinic; Clinical; Commit; Custom; Development; Disease; Disease Pathway; Distant; Early Diagnosis; Evaluation; Funding; Grant; Health; Human; Human Resources; Institution; Investigation; Laboratories; Maintenance; Mass Spectrum Analysis; Ohio; Outcome; Peptide Sequence Determination; Productivity; Program Research Project Grants; Research; Research Personnel; Research Project Grants; Resolution; Resources; Sampling; Schedule; Sensitivity and Specificity; Services; Technology; Time; Travel; Universities; analytical tool; base; instrument; instrumentation; mass spectrometer; member; metabolomics; novel; operation; prognostic; programs; public health relevance; translational study

DESCRIPTION (provided by applicant): The purpose of this proposal is to seek funds for the purchase of an LTQ OrbiTrap XL Mass Spectrometer. This instrument will expand and upgrade mass spectrometry capabilities within the Northeastern Ohio region, advancing research programs within the Cleveland Clinic (CC) and its partner institution, Case Western Reserve University (CWRU) other Cleveland CTSA member institutions and Cleveland State University (CSU). Major Users all have NIH-funded research grants, including recent multiple Program Project Grants and SCCOR programs, all which have Projects that rely heavily on using mass spectrometry to ask, investigate and answer key questions concerning major diseases that affect human health. Due to the absence of available high resolution instrumentation in the region for metabolomics-based studies the Major Users in this proposal now have to schedule time many months in advance to obtain access to this technology and/or travel to distant (>550 miles) institutions. As detailed in the application, supported projects primarily include biomarker discovery and clinical/translational studies nearly all of which also utilize the NCRR-funded Cleveland CTSA. The requested mass spectrometer provides the high resolution capabilities that allow unbiased metabolomics studies to be performed. Availability of this instrument will assure area investigators access high resolution mass spectrometry, while enhancing the versatility, sensitivity and specificity required for their projects. This analytical activity will be conducted within our existing Mass Spectrometry Core II, which provides support to investigators at CC, CWRU, CSU and neighboring institutions by performing structural elucidation studies, biomarker quantification, protein sequencing/identification, and related services. Mass spectrometry is increasingly being used as an analytical tool by CC and partner institution investigators, with demand greatly outpacing availability, resulting in significant delays in access, and hampered productivity. The acquisition of the requested mass spectrometer is essential to provide an unmet need for instrumentation to perform metabolomics-based investigations. Cleveland Clinic has committed substantial resources to the development of mass spectrometry in the region, including custom renovation of laboratory space for Mass Spectrometry Core II, personnel to oversee its operation, and a fiscal plan to insure its operation and maintenance for the long-term. PUBLIC HEALTH RELEVANCE: The major users group, of this shared mass spectrometry instrumentation grant, direct multiple very large clinical sample-based NIH-funded grants. The Major Users have projects that require the use of the requested instrumentation to ask, investigate and answer key questions concerning major diseases that affect human health. These projects primarily include disease biomarker discovery and clinical/translational studies that will allow and facilitate discovery of novel disease pathways and metabolites, early detection of disease states and/or provide prognostic evaluation of the disease state based upon clinical sample outcomes.

描述（由申请人提供）：该提案的目的是寻求购买LTQ Orbitrap XL质谱仪的资金。该工具将扩大和升级俄亥俄州东北部地区的质谱能力，推进克利夫兰诊所（CC）及其合作伙伴机构Case Western Reserve University（CWRU）的研究计划，克利夫兰CTSA成员机构和克利夫兰州立大学（CSU）。主要用户都拥有NIH资助的研究补助金，其中包括最近的多个计划项目赠款和SCCOR计划，所有这些项目都严重依赖于使用质谱法来询问，调查和回答有关影响人类健康的主要疾病的关键问题。由于基于代谢组学研究的地区没有可用的高分辨率仪器，因此该提案中的主要用户现在必须提前数月安排时间以获取该技术和/或前往远处（> 550英里）机构的访问。如应用程序中所述，受支持的项目主要包括生物标志物发现和临床/翻译研究，几乎所有这些研究都使用了NCRR资助的Cleveland CTSA。请求的质谱仪提供了高分辨率功能，可以进行无偏的代谢组学研究。该工具的可用性将确保区域调查人员访问高分辨率质谱，同时增强其项目所需的多功能性，灵敏度和特异性。这种分析活性将在我们现有的质谱核心II中进行，该核心核心II通过进行结构阐明研究，生物标志物定量，蛋白质测序/识别和相关服务，为CC，CWRU，CSU和邻近机构的研究人员提供支持。 CC和合作伙伴机构调查人员越来越多地将质谱法用作分析工具，需求大大超过了可用性，从而导致访问的大量延迟和妨碍生产率。获得所需的质谱仪的获取对于提供对基于代谢组学调查的仪器的未满足需求至关重要。克利夫兰诊所已为该地区的质谱开发提供了大量资源，包括对质谱核心II的实验室空间进行定制翻新，监督其运营的人员以及一项财政计划，以确保其长期运作和维护。 公共卫生相关性：该共享质谱工具拨款的主要用户组指导多个非常大的基于临床样本的NIH资助的赠款。主要用户的项目需要使用请求的仪器来询问，调查和回答有关影响人类健康的主要疾病的关键问题。这些项目主要包括疾病生物标志物发现和临床/翻译研究，这些研究将允许并促进发现新型疾病途径和代谢产物的发现，早期发现疾病状态和/或基于临床样本结果对疾病状态进行预后评估。